Ultragenyx is trading 6.07% down at $15.62 after its November 3 earnings release and corporate update, with reports citing missed revenue estimates and a quarterly loss slightly above consensus. - Revenue was $173 million; the company announced an approximately 20% workforce reduction. - Ultragenyx discontinued its UX701 Wilson disease program after the study failed to meet advancement criteria. - It reaffirmed its 2026 revenue outlook and 2027 profitability target; no pre-market trading volume was provided.